Overview
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for GH Research PLC as of June 30, 2025 is -52.99 MM.
- The net income for GH Research PLC as of June 30, 2025 is -41.02 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -52.99 | -41.02 | |
2025-03-31 | -51.52 | -42.11 | |
2024-12-31 | -50.25 | -38.96 | |
2024-09-30 | -48.48 | -41.43 | |
2024-06-30 | -45.59 | -34.97 | |
2024-03-31 | -42.08 | -32.32 | |
2023-12-31 | -41.22 | -35.59 | |
2023-09-30 | -39.35 | -40.90 | |
2023-06-30 | -36.24 | -35.69 | |
2023-03-31 | -33.29 | -27.63 | |
2022-12-31 | -30.68 | -22.46 | |
2022-09-30 | -28.00 | -9.96 | |
2022-06-30 | -26.04 | -11.36 | |
2022-03-31 | -21.97 | -13.82 | |
2021-12-31 | -15.10 | -9.20 | |
2021-09-30 | -8.80 | -5.44 | |
2021-06-30 | -4.20 | -3.66 | |
2021-03-31 | -1.57 | -1.58 | |
2020-12-31 | -0.45 | -0.45 |
Income Statement: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | -0.75 | |
2024-09-30 | -0.80 | -0.80 |
2024-06-30 | -0.67 | -0.67 |
2024-03-31 | -0.62 | -0.62 |
2023-12-31 | -0.68 | |
2023-09-30 | -0.79 | -0.79 |
2023-06-30 | -0.69 | -0.69 |
2023-03-31 | -0.53 | -0.53 |
2022-12-31 | -0.43 | |
2022-09-30 | -0.19 | -0.19 |
2022-06-30 | -0.22 | -0.22 |
2022-03-31 | -0.28 | -0.28 |
2021-12-31 | -0.21 | |
2021-09-30 | -0.14 | -0.14 |
2021-06-30 | -0.11 | -0.11 |
2021-03-31 | -0.05 | -0.05 |
2020-12-31 | -0.02 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for GH Research PLC as of June 30, 2025 is -40.29 MM.
- The cash from investing activities for GH Research PLC as of June 30, 2025 is 64.16 MM.
- The cash from financing activities for GH Research PLC as of June 30, 2025 is 139.67 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -40.29 | 64.16 | 139.67 |
2025-03-31 | -41.26 | 68.19 | 140.62 |
2024-12-31 | -42.28 | 65.14 | -0.30 |
2024-09-30 | -39.92 | 43.78 | -0.29 |
2024-06-30 | -37.96 | 28.49 | -0.28 |
2024-03-31 | -36.05 | 8.71 | -0.20 |
2023-12-31 | -33.34 | -54.10 | -0.20 |
2023-09-30 | -32.12 | -138.72 | -0.16 |
2023-06-30 | -29.82 | -138.72 | -0.11 |
2023-03-31 | -27.08 | -138.70 | -0.07 |
2022-12-31 | -26.20 | -84.69 | |
2022-09-30 | -23.09 | -0.07 | -0.17 |
2022-06-30 | -24.26 | -0.10 | -2.77 |
2022-03-31 | -20.20 | -0.09 | 286.45 |
2021-12-31 | -15.28 | -0.10 | 286.45 |
2021-09-30 | -11.67 | -0.09 | 292.12 |
2021-06-30 | -2.54 | -0.04 | 294.72 |
2021-03-31 | -1.31 | -0.02 | 5.50 |
2020-12-31 | -0.33 | 5.50 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/book for GH Research PLC as of June 30, 2025 is 2.45.
- The p/tbv for GH Research PLC as of June 30, 2025 is 2.45.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 2.45 | 2.45 | |
2025-03-31 | 3.83 | 3.83 | |
2024-12-31 | 2.06 | 2.06 | |
2024-09-30 | -10.24 | 1.80 | 1.80 |
2024-06-30 | -19.30 | 2.97 | 2.97 |
2024-03-31 | -15.66 | 2.54 | 2.54 |
2023-12-31 | -7.22 | 1.31 | 1.31 |
2023-09-30 | -14.60 | 2.24 | 2.24 |
2023-06-30 | -22.34 | 2.55 | 2.55 |
2023-03-31 | -18.42 | 1.66 | |
2022-12-31 | 1.97 | 1.97 | |
2022-09-30 | 2.29 | 2.29 | |
2022-06-30 | -37.58 | 1.93 | 1.93 |
2022-03-31 | -104.13 | 3.46 | 3.46 |
2021-12-31 | -222.97 | 4.27 | 4.27 |
2021-09-30 | -307.01 | 3.90 | 3.90 |
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for GH Research PLC as of June 30, 2025 is -0.08.
- The ebit (3y)/ev for GH Research PLC as of June 30, 2025 is -0.07.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.08 | -0.07 |
2025-03-31 | -0.07 | -0.06 |
2024-12-31 | -0.14 | -0.11 |
2024-09-30 | -0.13 | -0.11 |
2024-06-30 | -0.06 | -0.05 |
2024-03-31 | -0.07 | -0.04 |
2023-12-31 | -0.20 | -0.09 |
2023-09-30 | -0.08 | -0.04 |
2023-06-30 | -0.05 | -0.03 |
2023-03-31 | -0.09 | -0.05 |
2022-12-31 | -0.04 | -0.02 |
2022-09-30 | -0.03 | -0.02 |
2022-06-30 | -0.06 | -0.02 |
2022-03-31 | -0.01 | -0.01 |
2021-12-31 | -0.01 | -0.00 |
2021-09-30 | -0.00 | -0.00 |
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 |
Management Effectiveness
- The roa for GH Research PLC as of June 30, 2025 is -0.20.
- The roe for GH Research PLC as of June 30, 2025 is -0.21.
- The roic for GH Research PLC as of June 30, 2025 is -0.14.
- The croic for GH Research PLC as of June 30, 2025 is 0.54.
- The ocroic for GH Research PLC as of June 30, 2025 is -0.13.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-06-30 | -0.20 | -0.21 | -0.14 | 0.54 | -0.13 |
2025-03-31 | -0.18 | -0.19 | -0.22 | 0.12 | -0.24 |
2024-12-31 | -0.18 | -0.19 | -0.22 | 0.02 | -0.21 |
2024-09-30 | -0.15 | -0.15 | -0.18 | -0.05 | -0.19 |
2024-06-30 | -0.13 | -0.13 | -0.15 | -0.13 | -0.17 |
2024-03-31 | -0.14 | -0.14 | -0.16 | -0.40 | -0.15 |
2023-12-31 | -0.16 | -0.16 | -0.18 | -0.75 | -0.14 |
2023-09-30 | -0.13 | -0.14 | -0.15 | -0.72 | -0.13 |
2023-06-30 | -0.10 | -0.10 | -0.15 | -0.72 | -0.13 |
2023-03-31 | -0.08 | -0.08 | -0.11 | -0.68 | -0.11 |
2022-12-31 | -0.03 | -0.04 | -0.04 | -0.09 | -0.09 |
2022-09-30 | -0.04 | -0.04 | -0.04 | -0.09 | -0.09 |
2022-06-30 | -0.05 | -0.05 | -0.04 | -0.10 | -0.09 |
2022-03-31 | -1.66 | -2.13 | -0.05 | 0.99 | -0.07 |
2021-12-31 | -0.92 | -0.96 | -0.03 | 0.98 | -0.04 |
2021-09-30 | -9.15 | -0.02 | 0.99 | -0.01 | |
2021-06-30 | -7.26 | -9.15 | -0.01 | 1.01 | -0.01 |
2021-03-31 | -3.13 | -3.94 | -0.37 | 0.97 | -0.30 |
2020-12-31 | -0.88 | -1.12 | -0.08 | 0.95 | -0.06 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 |
Identifiers and Descriptors
Central Index Key (CIK) | 1855129 |
Industry Groups
SIC 2834 - Pharmaceutical Preparations |